|
|
||||||||
Cystic Fibrosis Research Laboratory, Stanford University, Stanford, California
Correspondence and requests for reprints should be addressed to Jeffrey J. Wine, M.D., Cystic Fibrosis Research Laboratory, Room 450, Building 420, Sierra Mall (Main Quad), Stanford University, Stanford, CA 94305-2130. E-mail: wine{at}stanford.edu; Web: http://www.stanford.edu/~wine/
| ABSTRACT |
|---|
|
|
|---|
Key Words: acetylcholine cystic fibrosis transmembrane conductance regulator pH vasoactive intestinal peptide
| MUCUS CLEARANCE |
|---|
|
|
|---|
Knowles and Boucher use two genetic diseases, CF and primary ciliary dyskinesia (PCD), to provide contrasting insights into the crucial role of mucus clearance in maintaining airway sterility (6). CF airway disease is explained by them approximately as follows. The loss of functional CFTR disinhibits the epithelial sodium channel and so increases absorption of isotonic liquid from the PCL layer (9). In normal airways, if the PCL layer thins beyond a critical point the surface epithelia somehow convert from absorptive to secretory (10). Presumably, the lack of CFTR prevents that in CF. Thus, in CF the gel-forming mucins that normally float above the cilia are brought into close contact with the airway surface, where they anneal to tethered mucins. The antimicrobials within these tethered mucus plaques soon become ineffective, and microbes proliferate. Conditions within the plaques, perhaps low O2 tension, contribute to the formation of a mucoid phenotype among the resident Pseudomonas aeruginosa, which thus become resistant to killing by the adaptive immune system. For PCD, mucociliary clearance is absent, but effective cough clearance remains. This can account for the milder airway disease observed in patients with PCD (6).
The hypothesis that defective mucus clearance accounts for CF lung disease was stated as early as 1945 by Farber, who coined the term mucoviscidosis (11). What differs in the modern reincarnation of the mucus clearance hypothesis is the insight that deficient water in the mucus, rather than altered mucin molecules, is the root cause of altered mucus clearance. Deficient water will increase the viscosity and tackiness of mucus, reduce the lubricating PCL layer, and so make it more difficult to clear mucus from gland ducts and airways. In this article, we provide additional data and arguments to support the hypothesis that defective mucus clearance is a critically important contributor to CF airway disease, and we propose that an important source of defective clearance is deficient fluid secretion from serous cells of submucosal glands. With the focus now sharpened, experimentation can be directed toward clarifying details of the system, for example, fluid secretion and absorption by surface and glandular cells, and the effects of an altered periciliary liquid layer and mucus gel. Our working hypothesis is that all of these elements are negatively affected by CFTR mutations, and it is their aggregate effects that lead to defective mucus clearance.
It is natural and useful for different groups to emphasize different aspects of the problem. Thus, while agreeing with the importance of the periciliary liquid (PCL) layer, in this review we emphasize the serous cell malfunction hypothesis: we propose that defects in the production and clearance of mucus from the glands themselves is a significant feature of cystic fibrosis airway disease (1). Evidence for this view comes from work by Engelhardt and coworkers (12), Inglis and coworkers (4), Yamaya and coworkers (2), Jiang and coworkers (3), and others. However, as requested by the editors, we emphasize our own work, which is aimed at determining exactly what submucosal glands are, how they work, what they have evolved to accomplish, and how they are affected in each disease state.
| MUCUS PRODUCTION BY SUBMUCOSAL GLANDS |
|---|
|
|
|---|
|
| METHODS FOR STUDYING GLAND SECRETION |
|---|
|
|
|---|
| GENERAL FINDINGS |
|---|
|
|
|---|
Responses to vasoactive intestinal peptide (VIP) and forskolin were studied in pigs and humans. In pigs, responses to forskolin required 1020 minutes to reach maximum and were then sustained. Responses for 231 glands measured in 26 pigs were 1.7 ± 0.2 nl · minute1 per gland, but the distribution showed marked kurtosis and was positively skewed. Responses to 1 µM VIP had a faster onset but were smaller than the response to 10 µM forskolin. For humans, responses to VIP/forskolin were quantified for a subset of glands in donor tracheas and in bronchi from subjects who were transplanted because of diseases other than CF. For 68 glands from donor tracheas, the secretion rate was 1.0 ± 0.2 nl · minute1 per gland. For 48 glands from subjects with non-CF diseases, the mean rate was 1.1 ± 0.4 nl · minute1 per gland.
For either kind of stimulation, rates of mucus secretion varied more than 10-fold among individual glands in all species. The tissue volumes of individual, microdissected glands also varied more than 10-fold, suggesting that gland size determines secretion rate. We have begun the tedious process of correlating, gland by gland, gland volume with secretory rate.
Inhibitors of Secretion and Effect on pH
Studies by Ballard and colleagues show that pig mucus secretion in response to acetylcholine (ACh) is inhibited by bumetanide or dimethyl amiloride, with the combination eliminating most secretion (4, 2225). We confirmed the bumetanide effect for average secretion by individual glands, suggesting that about half the volume of secretion depends on the Na+,K+,2Cl cotransporter. In an attempt to determine the contribution of HCO3 secretion we removed all HCO3, maintained the pH with N-2-hydroxyethylpiperazine-2',2-ethanesulfonic acid (HEPES), and pregassed with pure O2. Under these conditions secretion was again reduced by about half, and the combination of HCO3 replacement plus bumetanide inhibited secretion by about 90%. For technical reasons we have not yet determined whether individual glands vary in their sensitivity to either inhibitor.
The Calu-3 model of serous cells secretes almost pure HCO3 in response to forskolin stimulation (26). Unexpectedly, we found that gland secretion in response to forskolin was inhibited at least as strongly by bumetanide as was secretion stimulated by carbachol, and inhibition of forskolin-stimulated secretion by HEPES replacement of HCO3 was no greater than that of bumetanide, and no greater than the HEPES effect on carbachol-stimulated secretion.
| SECRETION BY CYSTIC FIBROSIS SUBMUCOSAL GLANDS |
|---|
|
|
|---|
We are now directly studying secretions of intact, individual CF submucosal glands to clarify these issues. Because glands contain mucous cells that do not appear to contain CFTR (12), the predicted defect in serous cell fluid secretion should be most easily detected if serous cells could be stimulated without activating mucous cell fluid secretion. Because CFTR is activated by elevations of [cAMP]i, we used VIP and forskolin to assess gland secretion in normal and CF glands. We discovered a complete absence of secretion in response to these mediators by glands from subjects with CF (1). Glands for lung donors, and glands from lungs of patients with diseases other than CF, responded well (Figure 2). Because the glands failed to respond to forskolin, which bypasses receptor pathways and activates adenylate cyclase directly, the defect cannot be secondary to the loss of VIP receptors, a possibility that is raised by the finding that VIP-containing nerves around sweat glands are decreased in patients with CF (34). Also, because the CF submucosal glands still responded to carbachol, the defect cannot be the result of a generalized defect in gland function. However, response of CF glands to carbachol differs quantitatively from responses of normal glands in several ways that are still being analyzed. All differences are consistent with a diminished mucous fluid content. A straightforward analysis is complicated because CF glands have volumes two to three times greater than control glands (3537).
|
| IONIC COMPOSITION OF PURE GLAND MUCUS |
|---|
|
|
|---|
| WORKING MODEL FOR SUBMUCOSAL GLANDS |
|---|
|
|
|---|
|
Mucous cells line tubules just proximal to the serous acini. Little is known directly about their ion and fluid transport mechanisms, but because virtually all gland fluid secretion is eliminated by the combination of bumetanide and HCO3 replacement, we infer that mucous cells, like serous cells, generate fluid secretion by transporting Cl and HCO3 into the gland lumen. Mucous cells secrete the bulk of the mucin molecules, and MUC5B is the predominant type (39). Mucus secretion (mucins, other proteins, water, and ions) is partially preserved in CF glands, yet no known mechanism exists for non-CFTR, anion-mediated fluid secretion from serous cells. Therefore, we hypothesize that water and ion secretions from mucous tubules occur via non-CFTR-dependent mechanisms (20). We propose that mucous cells secrete fluid and mucin molecules in response to ACh, but in response to VIP they release only proteins via exocytosis. This conclusion is based on the complete absence of mucus secretion from CF glands exposed to VIP or forskolin.
The collecting duct epithelium consists of columnar cells up to 70 µm in height and containing abundant mitochondria (16). Their function is unknown, but Meyrick and Reid, who first described the collecting duct, pointed out that it is strategically located to monitor and condition all serous and mucous cell secretions on their way to the surface (16). We hypothesize that the collecting duct scavenges HCO3, possibly converting it to CO2 and water, that Na+ is also absorbed, and that either an osmolyte is added or the solution is able to remain hypotonic. This is based on the premise that serous cells, like Calu-3 cells, secrete a HCO3-rich fluid in response to elevations of [cAMP]i (26), yet the final mucus collected at the mouth of the duct has a pH between 7 and 7.2 versus a bath pH of 7.4 whether stimulated by ACh or VIP/forskolin (21). Furthermore, we find no difference in the pH of CF and control glands (20), in spite of the prediction that CF glands lack the HCO3 component from serous cells. Finally, secretions from bronchial submucosal glands (20) and nasal glands (33) of both control and CF subjects have significantly less Na+, Cl, and HCO3 than the bath. All of these findings indicate that the acinar fluid is modified extensively in the collecting and ciliated ducts, and is perhaps homeostatically controlled to bring it to a final common composition in spite of changes in the primary secretions.
The ciliated duct may simply be a continuation of the surface ciliated epithelial cells, in which case it would be primarily absorptive and able to acidify secretions via H+,K+-ATPase (43). However, the environment and functional role of the ductal cells differ considerably from those of the surface epithelium, and we hypothesize that the ciliated duct cells have a specialized phenotype.
To summarize, in this model ion-mediated water secretion from serous cells depends absolutely on CFTR, whereas ion-mediated water secretion from mucous cells is CFTR independent. ACh and other transmitters that elevate [Ca2+]i activate ion, water, and macromolecular secretion from both serous and mucous cells, which are then mixed and conditioned in the ducts. Transmitters that elevate [cAMP]i stimulate exocytosis and fluid secretion from serous cells, but only exocytosis of mucin from mucous cells. The CFTR-dependent, fluid-secreting serous cell pathway is deleted in cystic fibrosis glands. Present goals are to test all aspects of the model, and to formulate testable hypotheses to explain how a lack of functional CFTR in the gland contributes to CF airway disease. Like all models, this one is incomplete and is likely to be wrong in important ways. For a different model of submucosal glands see Shimura (44).
| CYSTIC FIBROSIS GLAND DEFECT: TOO LITTLE WATER, TOO LATE |
|---|
|
|
|---|
Ballard and colleagues have shown the consequences of stimulating gland secretion in the almost complete absence of fluid secretion. They used inhibitors to block about 90% of fluid secretion from glands and surface epithelia, and then stimulated mucin secretion with ACh. That resulted in extremely viscous mucus that plugged the glands (23, 25, 27). It is fortunate that the CF phenotype is not so extreme. In CF airways, partial fluid secretion continues via non-CFTR pathways (1), which we propose are localized in mucous cells and possibly surface goblet cells; alternate pathways in CFTR-containing cells may also exist or be induced. Such residual secretion prevents a catastrophic failure of mucus clearance in CF airways. Indeed, many authors have made the point that mucociliary clearance in CF airways is slowed, not absent. In an important paper, Regnis and colleagues showed that slower clearance in patients with CF was in part secondary to their lung infections, with more severe infections associated with slower clearance. In patients with CF with milder infections, average clearance was about 60% of the normal rate (45).
Fortunately, in spite of a the total loss of secretion to VIP and forskolin in CF glands, glands retain the ability to secrete partially in response to ACh, which is the most important physiological transmitter. The model of gland function shown in Figure 3 predicts that all fluid secretion from CF glands originates from mucous cells. Because CF submucosal glands are two to three times larger than normal glands (3537), they can maintain a near-normal volume of mucus secretion, but viscosity is increased (20) and the disposition of serous cell antimicrobials within the mucus may be suboptimal.
| CYSTIC FIBROSIS AIRWAY DISEASE: MULTIFACTORIAL HYPOTHESIS |
|---|
|
|
|---|
It seems necessary to propose a multifactorial hypothesis to account for CF airway disease. We propose that loss of CFTR-mediated fluid secretion by gland serous cells and surface epithelial cells leads to underhydration of airway mucus and thinning of the periciliary liquid layer. This is exacerbated by increased fluid absorption caused by disinhibition of the epithelial sodium channel. Viscous mucus and the shallower periciliary liquid layer cause a modest slowing of mucociliary transport and probably also cause a modest decrease in the overall efficiency of cough clearance. However, we suggest that these effects are insufficient to explain the early onset, heterogeneous distribution, and life-long persistence of CF airway bacterial infections.
What distinguishes CF from all other obstructive lung diseases is the complete loss of a special kind of secretion: the HCO3-rich fluid secretion from gland serous cells, which we propose leads to premature gelling of abnormally concentrated CF mucus within the thin and multiply branched tubules of submucosal glands. (Note that the concept of a deficient periciliary liquid layer, if important in the airways, should be even more critical in the small-diameter ducts of the glands.) We propose that idiosyncratic features of airway glands may cause a small proportion of them to develop tethered mucus plugs that persist for days, weeks, or months within the airways. These long-resident plugs continue to bind bacteria, but it has been shown, at least for nasal mucus, that microbes cocultured with mucus start to proliferate after a suppression period lasting as little as 24 hours (8).
The persistence of pathogens in the airway mucus is detected by macrophages patrolling the periciliary liquid layer, which release an array of cytokines to trigger an adaptive immune response (47). This includes an influx of inflammatory cells, especially neutrophils, into the submucosa and the airway lumen. The adaptive inflammatory immune response is essential, but we hypothesize that its success, and especially its resolution, also depend critically on the patency of mucus clearance. If clearance is impaired, spent inflammatory cells and their toxic products accumulate, host tissues are damaged, and more inflammatory cells are recruited. This destructive cycle is progressive.
In addition to stasis, CF airway mucus may be inherently less hostile to certain organisms than normal mucus (48). Definitive experiments to test this possibility are difficult because of access problems, but not only that. The ability of normal mucus to suppress pathogen growth almost certainly depends on synergistic actions among its complex components, which range from water and electrolytes to cells (49). Thus, the loss of CFTR-mediated electrolyte and fluid transport might impair the chemical shield of mucus in addition to its profound effects on clearance.
The multifactorial mucus clearance hypothesis of CF airway disease is consistent with the obstructive pathology characteristic of other CF organs that secrete mucus or macromolecules, including the sinuses, vas deferens, pancreas, and intestine, which become partially or completely filled with inspissated secretions, leading in some cases to complete blockage and degeneration (5052). There is an emerging consensus that inadequate hydration of epithelial fluids, secondary to the loss of CFTR, underlies all of this pathology.
| SUBMUCOSAL GLANDS AND PCD AIRWAY DISEASE |
|---|
|
|
|---|
| UNANSWERED QUESTIONS AND ADDITIONAL MECHANISMS |
|---|
|
|
|---|
What Is the Role of VIP-stimulated Gland Secretion?
In spite of an extensive literature (13), our present understanding of the normal role of VIP and non-VIP pathways in controlling gland secretions is inadequate to predict the consequences of the absolute defect we discovered in VIP- and forskolin-mediated fluid secretion by CF glands. We need to know in much more detail how the nervous system controls the airway submucosal glands. In the absence of such evidence, we can only speculate that VIP pathways (or more generally all pathways capable of mediating serous cell-dominated secretion) may be involved in airway health via mechanisms very different from those emphasized in this review. One example is the modulation of inflammation (57).
Does CF Disease Start in Small Airways?
It is often stated that CF lung disease begins in small airways, and therefore gland dysfunction is discounted as a primary contributor to CF airway disease. However, we are unaware of definitive evidence that bacterial airway infections or mucus plugging in patients with CF generally begins in the smallest bronchioles and then spreads to the larger airways. Glands are found in cartilagenous airways as small as 12 mm, as they enter pulmonary lobules. High-resolution computed tomography of CF lungs clearly shows evidence of peripheral air trapping and bronchial wall thickening as the earliest signs of disease, but inspection of published figures suggests that the regions of earliest air trapping are usually large enough to be explained by restrictions in the smallest gland-containing bronchi (58). Moreover, the extreme heterogeneity of CF disease is difficult to explain by a mechanism whereby the airways "fill up" from the smallest to largest airways, but is rather more consistent with intermittent plugging of larger airways.
What Mechanisms Are Required for the Dispersion of Exocytosed Granules?
Preliminary observations in our laboratory of ongoing mucus formation in single glands support prior evidence (53) that exocytosed material may remain as condensed packets for a long time after secretion. We hypothesize that the process whereby these packets of material are dispersed within mucus may be defective in CF airway glands. This hypothesis is based on a comparison of airway gland secretion with secretion in the intestinal crypts. Paneth cells can be thought of as the serous cells of the intestinal crypts. In a landmark study, Clarke and colleagues have shown that in CF mice, Paneth cell granule contents are trapped as undispersed packets within crypt lumen (59, 60). The mechanism for this is unknown, but may be related to deficient HCO3 and water secretion by the CF mouse crypts. If a similar phenomenon occurs within airway submucosal glands, the effectiveness of antimicrobials would be greatly diminished, even though their concentrations, as assayed by typical methods, might be unchanged. We need to know whether this does, in fact, occur.
What Interventions Should Work?
The characterization of CF lung disease presented above leads us to propose an intervention strategy that departs significantly from present practices. The main lesson of innate defense is that it is constantly vigilant, attacking immediately when pathogens are least numerous and most susceptible. We suggest that the closest strategy to compensate for the compromised innate defenses in CF lungs is a daily regimen of clearance (exercise may be best, but this is highly individualistic) followed by inhaled antibiotics. (If clearance methods were effective, inhaled antibiotics might not be required.) Because we think that CF lung disease starts with localized airway obstruction and infection, pulmonary function tests are inadequate to give early warnings. A marked improvement is to combine them with high-resolution computed tomography scans (61); the greatly reduced radiation levels of modern scanners makes that feasible.
There are, of course, objections to these strategies, the most usual being a fear of developing antibiotic resistance, the high cost of treatments, and the time required. However, the most effective treatment strategies that have passed muster in controlled trials come close to this model (62), except that they commence only after patients have become chronically infected. As similar trials are run in ever younger patients, we think it likely that the field will eventually converge on the model suggested by studies of airway innate defenses.
Conclusions
Our working hypothesis is that secretion by CF submucosal glands lacks the electrolyte-driven fluid component normally supplied by serous cells. Macromolecular secretion by both serous and mucous cells, and electrolyte-driven fluid secretion by mucous cells, are hypothesized to be intact. Because the rheologic properties of mucus depend critically on the concentration of macromolecules during initial formation of the gel and are resistant to subsequent changes, we hypothesize that a deficiency in electrolyte-driven water transport deep within the gland tubules will increase the concentration of gland mucus, adversely affecting mucus clearance from the glands and dispersal of antimicrobials, and contributing to impaired mucociliary and cough clearance.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
(Received in original form June 19, 2003; accepted in final form August 29, 2003)
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
R. J. Lee and J. K. Foskett Mechanisms of Ca2+-stimulated fluid secretion by porcine bronchial submucosal gland serous acinar cells Am J Physiol Lung Cell Mol Physiol, February 1, 2010; 298(2): L210 - L231. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rafferty, N. Alcolado, C. Norez, F. Chappe, S. Pelzer, F. Becq, and V. Chappe Rescue of Functional F508del Cystic Fibrosis Transmembrane Conductance Regulator by Vasoactive Intestinal Peptide in the Human Nasal Epithelial Cell Line JME/CF15 J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 2 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S. Joo, J. J. Wine, and A. W. Cuthbert Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans Am J Physiol Lung Cell Mol Physiol, May 1, 2009; 296(5): L811 - L824. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Fischer, K. L. Goss, T. E. Scheetz, C. L. Wohlford-Lenane, J. M. Snyder, and P. B. McCray Jr. Differential Gene Expression in Human Conducting Airway Surface Epithelia and Submucosal Glands Am. J. Respir. Cell Mol. Biol., February 1, 2009; 40(2): 189 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Chappe, M. E. Loewen, J. W. Hanrahan, and V. Chappe Vasoactive Intestinal Peptide Increases Cystic Fibrosis Transmembrane Conductance Regulator Levels in the Apical Membrane of Calu-3 Cells through a Protein Kinase C-Dependent Mechanism J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 226 - 238. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Rogers, W. M. Abraham, K. A. Brogden, J. F. Engelhardt, J. T. Fisher, P. B. McCray Jr., G. McLennan, D. K. Meyerholz, E. Namati, L. S. Ostedgaard, et al. The porcine lung as a potential model for cystic fibrosis Am J Physiol Lung Cell Mol Physiol, August 1, 2008; 295(2): L240 - L263. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Lee, J. M. Harlow, M. P. Limberis, J. M. Wilson, and J. K. Foskett HCO3- Secretion by Murine Nasal Submucosal Gland Serous Acinar Cells during Ca2+-stimulated Fluid Secretion J. Gen. Physiol., July 1, 2008; 132(1): 161 - 183. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. J. Broughton-Head, J. Shur, M. P. Carroll, J. R. Smith, and J. K. Shute Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis Am J Physiol Lung Cell Mol Physiol, November 1, 2007; 293(5): L1240 - L1249. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Haggie and A. S. Verkman Cystic Fibrosis Transmembrane Conductance Regulator-independent Phagosomal Acidification in Macrophages J. Biol. Chem., October 26, 2007; 282(43): 31422 - 31428. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Liu and J. M. Farley Sr. Prostaglandin E2 Enhances Acetylcholine-Induced, Ca2+-Dependent Ionic Currents in Swine Tracheal Mucous Gland Cells J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 501 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R. de Jonge Cystic fibrosis mice rehabilitated for studies of airway gland dysfunction J. Physiol., April 1, 2007; 580(1): 7 - 8. [Full Text] [PDF] |
||||
![]() |
J. P. Ianowski, J. Y. Choi, J. J. Wine, and J. W. Hanrahan Mucus secretion by single tracheal submucosal glands from normal and cystic fibrosis transmembrane conductance regulator knockout mice J. Physiol., April 1, 2007; 580(1): 301 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Livraghi and S. H. Randell Cystic Fibrosis and Other Respiratory Diseases of Impaired Mucus Clearance Toxicol Pathol, January 1, 2007; 35(1): 116 - 129. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. V. Wu, M. E. Krouse, and J. J. Wine Acinar origin of CFTR-dependent airway submucosal gland fluid secretion Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L304 - L311. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Cantin, J. W. Hanrahan, G. Bilodeau, L. Ellis, A. Dupuis, J. Liao, J. Zielenski, and P. Durie Cystic Fibrosis Transmembrane Conductance Regulator Function Is Suppressed in Cigarette Smokers Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1139 - 1144. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S. Joo, T. Irokawa, R. C. Robbins, and J. J. Wine Hyposecretion, Not Hyperabsorption, Is the Basic Defect of Cystic Fibrosis Airway Glands J. Biol. Chem., March 17, 2006; 281(11): 7392 - 7398. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Irokawa, M. E. Krouse, N. S. Joo, J. V. Wu, and J. J. Wine A "virtual gland" method for quantifying epithelial fluid secretion Am J Physiol Lung Cell Mol Physiol, October 1, 2004; 287(4): L784 - L793. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |